![Esperion Therapeutics, Inc. logo](/logos/ESPR.webp)
Esperion Therapeutics, Inc.
NASDAQ:ESPR
Overview | Financials
Company Name | Esperion Therapeutics, Inc. |
Symbol | ESPR |
Currency | USD |
Price | 1.65 |
Market Cap | 323,771,250 |
Dividend Yield | 0% |
52-week-range | 0.7 - 3.4 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Sheldon L. Koenig |
Website | https://www.esperion.com |
An error occurred while fetching data.
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD